Scarica l'app Stockscreener
3.87
6.03%
0.22
Dopo l'orario di chiusura:
3.87
Precedente Chiudi:
$3.65
Aprire:
$3.65
Volume 24 ore:
95,642
Relative Volume:
0.59
Capitalizzazione di mercato:
$26.64M
Reddito:
$5.21M
Utile/perdita netta:
$-26.35M
Rapporto P/E:
-0.1206
EPS:
-32.0862
Flusso di cassa netto:
$-20.84M
1 W Prestazione:
+1.04%
1M Prestazione:
-11.44%
6M Prestazione:
+1,597%
1 anno Prestazione:
+701.24%
Intervallo 1D:
$3.62
$3.95
Intervallo di 1 settimana:
$3.55
$3.95
Portata 52W:
$0.129
$8.00
Plus Therapeutics Inc Stock (PSTV) Company Profile
Nome
Plus Therapeutics Inc
Settore
Industria
Telefono
737.255.7194
Indirizzo
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
3.87 | 25.68M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-03 | Iniziato | Lake Street | Buy |
| 2025-09-03 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Iniziato | D. Boral Capital | Buy |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-10-16 | Iniziato | Maxim Group | Buy |
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference - Yahoo! Finance Canada
PSTV|Plus Therapeutics Inc|Price:3.770|Chg%:-0.060 - TradingKey
Plus Therapeutics Inc (PSTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Plus Therapeutics Inc (PSTV) Cash Flow - TradingKey
Plus Therapeutics Inc (PSTV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Plus Therapeutics Inc (PSTV) Income Statement - TradingKey
Plus Therapeutics Inc (PSTV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PLUS THERAPEUTICS Inc. (PSTV) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Plus Therapeutics Inc (PSTV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Plus Therapeutics Inc. R (XMP1.DU) stock price, news, quote and history - Yahoo Finance UK
Plus Therapeutics Inc (PSTV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Plus Therapeutics, Inc. (PSTV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Plus Therapeutics secures regional coverage for... - Pluang
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - The Manila Times
CNSide Diagnostics signs coverage deal with Medical Mutual - Investing.com
CNSide Diagnostics signs coverage deal with Medical Mutual By Investing.com - Investing.com Canada
Plus Therapeutics Secures Regional Coverage Agreement with - GlobeNewswire
Plus Therapeutics Inc. R (XMP1.DU) valuation measures and financial statistics - Yahoo Finance UK
PLUS THERAPEUTICS INC (PSTV) Stock Chart - ChartMill
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform - Sahm
Plus Therapeutics partners with GTC on CSF diagnostic platform - Investing.com UK
Plus Therapeutics partners with GTC on CSF diagnostic platform By Investing.com - Investing.com Nigeria
Plus Therapeutics (PSTV) Forms Partnership for Advanced Biomarker Profiling - GuruFocus
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring - Sahm
NCCN updates guidelines for leptomeningeal metastases diagnosis - Investing.com UK
Plus Therapeutics (PSTV) Updates NCCN Guidelines for CNS Cancers - GuruFocus
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines - GlobeNewswire
Guidelines call for spinal-fluid checks every 4–8 weeks during therapy - Stock Titan
PLUS THERAPEUTICS (PSTV) Surges 7%: Biotech Momentum Testing Key ResistanceFair Value Gap - DonanımHaber
Plus Therapeutics subsidiary enrolls in Medicare program - Investing.com
PSTV Should I Buy - Intellectia AI
PLUS THERAPEUTICS Inc. (PSTV) Q1 2026 Earnings: Wider Loss Per Share Overshadows Clinical ProgressProfit Growth Outlook - dars.gov.et
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J - Moomoo
Plus Therapeutics (PSTV) CEO gains 16,439 shares from RSU vesting - Stock Titan
PLUS Therapeutics (PSTV) director converts 922 RSUs into common stock - Stock Titan
Plus Therapeutics (NASDAQ: PSTV) director gains 922 shares via RSU vesting - Stock Titan
PLUS Therapeutics (PSTV) CFO converts RSUs into 2,985 common shares - Stock Titan
[Form 4] PLUS THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
Plus Therapeutics provides mid-year business update including corporate rebranding - MSN
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY - Investing.com UK
Plus Therapeutics Advances REYOBIQ Clinical Trials and Manufacturing Progress - marketscreener.com
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV) - Yahoo Finance
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY By Investing.com - Investing.com South Africa
Plus Therapeutics to Rebrand as Cerenome, Affirm 2026 Guidance and Report CNSide Commercial Progress - Quiver Quantitative
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding - GlobeNewswire
Price to earnings forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to EBITDA forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to EBIT forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Price to sales forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to revenue forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell 3000E Index - marketscreener.com
Plus Therapeutics Inc Azioni (PSTV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Plus Therapeutics Inc Azioni (PSTV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ANDREWS RONALD ASBURY | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
922 |
| van Es-Johansson An | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
922 |
| HEDRICK MARC H | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
0.00 |
16,439 |
0 |
44,483 |
| Clowes Howard | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
1,981 |
| Hawkins Richard J | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
1,529 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Jul 01 '26 |
Option Exercise |
0.00 |
2,985 |
0 |
9,941 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
67,452 |
0 |
173,913 |
| HEDRICK MARC H | Chief Executive Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
499,468 |
| HEDRICK MARC H | Chief Executive Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
339,787 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
38,323 |
0 |
106,461 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):